Inhibition of G9a can be a promising approach to selectively block NF-κB pathway in MM, reversing RelB-mediated transcriptional repression of proapoptotic genes, such as Bim and BMF. The increased expression of G9a and effect of G9a loss-of-function on MM cells makes G9a an attractive target for inhibiting NF-κB-related processes in MM. The gene discussed is NFKB1; the disease is Miyoshi myopathy.